Region Uppsala

The site is advancing therapies for heart failure with preserved ejection fraction and preventing major cardiovascular events.

• Beta‑blocker strategy for COPD patients to reduce cardiovascular risk
• Spironolactone or eplerenone added to standard care to lower HF hospitalizations
• Baxdrostat combined with dapagliflozin to reduce heart‑failure events
• Prevention of heart failure in at‑risk populations

These studies are coordinated through the Region Uppsala primary‑care research network.

Research focuses on chronic lung disease and acute respiratory conditions, including Chronic Obstructive Pulmonary Disease and ARDS.

• Beta‑blocker trial to protect COPD patients from exacerbations, cardiovascular events and death
• Triple inhaler therapy versus dual bronchodilator for severe cardiopulmonary outcomes
• Mesenchymal stromal cell therapy for acute respiratory distress syndrome

The programme benefits from close collaboration with the local pulmonary department at Uppsala University Hospital.

Studies aim to improve skin health and wound healing, with a focus on atopic dermatitis and diabetic foot ulcers.

• Comparison of moisturisers for time to eczema relapse
• Evaluation of local antimicrobial agents to accelerate diabetic foot ulcer healing
• Investigation of hormonal contraceptives on skin structure and function

The dermatology team works together with the Swedish Dermatology Society to ensure rigorous trial conduct.

Trials target immune pathways such as complement activation in renal disease and viral immunity.

• Aliskiren versus enalapril to block complement activation in C3 glomerulopathy
• SGLT2‑inhibitor versus metformin for early type 2 diabetes with immune‑metabolic benefits
• Population‑level HPV vaccination and screening to reduce viral infection rates

These investigations are supported by the Swedish Institute for Health Economics.

The centre conducts trials that use biomarker profiling to match patients with targeted cancer therapies.

• Nationwide clinical trial to facilitate patient access to biomarker‑driven cancer treatments
• Evaluation of novel agents in advanced cancer cohorts

Oncology research is integrated with the Uppsala Cancer Center for translational support.

Focused on prevention and early detection of HPV infection and related cervical disease.

• Concomitant HPV vaccination and screening to accelerate elimination of infection
• Study of cervical intraepithelial neoplasia grades 2‑3 management strategies

The program aligns with the national Swedish cervical screening program coordinated by Public Health Agency of Sweden.

Clinical work addresses early type 2 diabetes and its cardiovascular complications.

• SGLT2‑inhibitor versus metformin for progression‑free survival in newly diagnosed T2D
• Baxdrostat combined with dapagliflozin to lower heart‑failure risk in diabetic patients

Metabolic research is conducted in partnership with the Swedish Diabetes Association.

Trials explore contraception and hormonal effects, including the impact of combined hormonal contraceptives on brain function.

• Brain structural and functional outcomes of E4/DRSP versus EE/LNG contraceptives
• Safety and efficacy assessment of modern combined hormonal contraceptives

The reproductive health studies are overseen by the Swedish Association of Midwives.

Research evaluates optimal treatment for bacterial infections such as Staphylococcus aureus bacteraemia.

• Comparison of benzylpenicillin and cloxacillin for penicillin‑susceptible S. aureus bacteraemia

Antimicrobial stewardship is guided by the Swedish Society of Clinical Microbiology.

Studies address acute and chronic symptom syndromes, including acute respiratory distress syndrome.

• Mesenchymal stromal cell therapy validation for ARDS clinical efficacy
• Evaluation of systemic symptom burden in chronic disease cohorts

Patient‑reported outcomes are collected in collaboration with the Swedish Patient Organization Network.